Denali Therapeutics Inc. (NASDAQ:DNLI) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) have received a consensus rating of “Moderate Buy” from the nine analysts that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is $38.33.

A number of equities analysts recently issued reports on DNLI shares. Bank of America increased their target price on shares of Denali Therapeutics from $25.00 to $29.00 and gave the company a “buy” rating in a research report on Wednesday, September 4th. HC Wainwright reaffirmed a “buy” rating and set a $90.00 price target on shares of Denali Therapeutics in a research note on Wednesday, September 4th. Wedbush cut their price objective on Denali Therapeutics from $30.00 to $26.00 and set an “outperform” rating for the company in a report on Friday, August 2nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $35.00 price target on shares of Denali Therapeutics in a research report on Monday, September 9th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Denali Therapeutics from $28.00 to $29.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 10th.

Denali Therapeutics Trading Down 1.6 %

NASDAQ DNLI opened at $28.67 on Wednesday. The company has a 50-day moving average price of $25.56 and a two-hundred day moving average price of $21.87. Denali Therapeutics has a 52 week low of $14.56 and a 52 week high of $32.13. The stock has a market cap of $4.09 billion, a price-to-earnings ratio of -29.86 and a beta of 1.37.

Denali Therapeutics (NASDAQ:DNLI) last announced its earnings results on Thursday, August 1st. The company reported ($0.59) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.09. The business had revenue of $1.00 million for the quarter, compared to the consensus estimate of $10.00 million. During the same period in the previous year, the firm earned $1.30 EPS. The firm’s revenue was down 99.7% on a year-over-year basis. As a group, equities research analysts expect that Denali Therapeutics will post -2.54 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Denali Therapeutics

Large investors have recently made changes to their positions in the company. GAMMA Investing LLC raised its stake in Denali Therapeutics by 879.5% during the 2nd quarter. GAMMA Investing LLC now owns 2,057 shares of the company’s stock valued at $48,000 after purchasing an additional 1,847 shares during the period. PNC Financial Services Group Inc. boosted its position in Denali Therapeutics by 48.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 2,486 shares of the company’s stock worth $53,000 after acquiring an additional 807 shares during the period. Fisher Asset Management LLC acquired a new position in shares of Denali Therapeutics in the 4th quarter valued at about $59,000. Headlands Technologies LLC purchased a new stake in shares of Denali Therapeutics in the first quarter worth approximately $88,000. Finally, SG Americas Securities LLC purchased a new position in Denali Therapeutics during the first quarter valued at approximately $147,000. Institutional investors and hedge funds own 92.92% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.